ClinicalTrials.gg
Sign In

BiosimilarDrug

QL2107 clinical trials

Also written QL2107.

A product of Pembrolizumab; its studies count on that page too.

studies test it
8
open now
7
in phase 3
3
first study started
2023

Keep track of what changes. Save the QL2107 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

QL2107 Injection
2

Development codes

QL2107
5

Studies by the year they started

8 studies that test it; most in 2025 (5)

Studies that test QL2107, by start year
YearStudies
20231
20255
20262

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
4
Phase 3
3

What it is tested for

Each study’s main condition, where its own words name it.

Carcinoma, Non-Small-Cell Lung
1
Small Cell Lung Carcinoma
1
Stomach Neoplasms
1
Adenocarcinoma
1

Who runs them

Industry 8 · Other 0

Qilu Pharmaceutical Co., Ltd. (8)

Often tested with

Tested in the same studies.

QLC5508 (1) · QLS5132 (1) · Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905 (1) · QLP2117 (1)

Studies

Open first, then newest update. How each study uses QL2107 is read from its arms, and is right about nine times in ten.

Testing it · 8

Given in every arm · 1 — QL2107 is usual care beside what is tested